Anatara Announces Exclusive Global License Agreement with Zoetis

15-May-2018 12:30 PM


 

Key points:

  • Anatara has signed an exclusive agreement with Zoetis Inc., the leading global animal health company, to license Detach® - Anatara’s non-antibiotic approach to aid in the control of diarrhoeal disease in livestock and horses
  • Zoetis to manage worldwide development, manufacturing, distribution and marketing of Detach® for livestock animals and horses
  • Agreement represents the achievement of a major milestone for Anatara and its shareholders
Dr Mel Bridges, Executive Chairman & CEO, Anatara Lifesciences (Photo: Business Wire)

Dr Mel Bridges, Executive Chairman & CEO, Anatara Lifesciences (Photo: Business Wire)



BRISBANE, Australia--()--Anatara Lifesciences (ASX:ANR) is delighted to announce an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide development, manufacture, distribution and marketing of Detach® as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses.

 

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180514006505/en/
 

Under the terms of the license agreement, Anatara has granted Zoetis exclusive rights to develop, manufacture, distribute and market Detach® worldwide, including in Australia. The agreement follows an initial Exclusive Research Evaluation and License Option period (announced 18th January 2016), during which time Zoetis evaluated Detach® for use as a non-antibiotic product in livestock species.

The terms of the agreement include an upfront payment, milestone payments and royalties based on product sales. Intellectual property exclusively licensed to Zoetis under the agreement shall remain the sole property of Anatara. Exact details of the agreement remain confidential.

Anatara’s Executive Chairman, Dr Mel Bridges said, “Through signing this agreement with Zoetis, Anatara has reached a major commercial milestone - this an exciting moment for our shareholders.”

Dr Bridges added, “The global reach and resources that Zoetis is able to apply to making Detach® a successful product is of great value to Anatara. We see this as an outstanding result with a world-leading partner.”

“Veterinarians and livestock farmers are seeking new, integrated solutions to help keep animals healthy,” said Dr. Scott A. Brown, Vice President, External Innovation at Zoetis. “We look forward to continuing our research and development of this novel approach and intend to explore its place in our diverse portfolio of solutions to prevent and treat gastrointestinal illness in livestock animals and horses.”

Anatara’s Detach® technology has the potential to play an important role as an alternative to traditional antibiotics to control gastrointestinal diseases in livestock and production animals. The agreement demonstrates both companies’ commitment to the responsible use of antibiotics in the food chain and finding natural alternatives to help control gastrointestinal disease.


Contacts

Anatara Lifesciences
Cherie Hartley, +61 (0) 418 737 020
cherie.hartley@irdepartment.com.au

Topic: Health

Media contact

Newsroom
Businesswire Australia and New Zealand

info@businesswire.com

About us

With thousands of distribution and targeting options that reach 162 countries in 50+ languages and 193 industry trade categories, Business Wire gives you access to the world's most powerful press release network. Built on our patented simultaneous and secure NX network and augmented with partnerships with international and national news agencies, Business Wire is a valued and trusted source for breaking news by reporters, investors and consumers.

More in Business Wire Australia and New Zealand